Metanoia Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1M
- Investors
-
5
Metanoia General Information
Description
Operator of a biotechnology research company intended for functional tissue regeneration. The company offers a proprietary platform based on modifying an evolutionarily conserved pathway for physiologically induced tissue regeneration, with diversified therapeutic applications in diabetes, diabetic retinopathy, pancreatic cancer, Alzheimer's Disease, and heart failure, enabling healthcare providers to gain access to technology and implement it in services.
Contact Information
Website
metanoia.bioCorporate Office
- 218 South Roxbury Drive
- Beverly Hills
- Los Angeles, CA 90212-3709
- United States
Corporate Office
- 218 South Roxbury Drive
- Beverly Hills
- Los Angeles, CA 90212-3709
- United States
Metanoia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 18-Mar-2026 | $1M | Completed | Generating Revenue | ||
| 3. Early Stage VC | Completed | Pre-Clinical Trials | ||||
| 2. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 1. University Spin-Out | 01-Jan-2020 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Metanoia Patents
Metanoia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022278550-A1 | Methods and compositions for treating cardiovascular disease | Pending | 16-May-2021 | ||
| CA-3218944-A1 | Methods and compositions for treating cardiovascular disease | Pending | 16-May-2021 | ||
| EP-4340835-A1 | Methods and compositions for treating cardiovascular disease | Pending | 16-May-2021 | ||
| EP-4340835-A4 | Methods and compositions for treating cardiovascular disease | Pending | 16-May-2021 | ||
| US-20240262916-A1 | Methods and compositions for treating cardiovascular disease | Pending | 16-May-2021 | C07K16/2857 |
Metanoia Signals
Metanoia Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abundance Capital (Greenville) | Not-For-Profit Venture Capital | Minority | ||
| OneBio Venture Studio | Venture Capital | Minority | ||
| University of California, Los Angeles | University | |||
| Healthspan Capital | Venture Capital | Minority | ||
| University of Toronto | University |
Metanoia FAQs
-
When was Metanoia founded?
Metanoia was founded in 2020.
-
Where is Metanoia headquartered?
Metanoia is headquartered in Los Angeles, CA.
-
What is the size of Metanoia?
Metanoia has 5 total employees.
-
What industry is Metanoia in?
Metanoia’s primary industry is Drug Discovery.
-
Is Metanoia a private or public company?
Metanoia is a Private company.
-
What is Metanoia’s current revenue?
The current revenue for Metanoia is .
-
How much funding has Metanoia raised over time?
Metanoia has raised $1M.
-
Who are Metanoia’s investors?
Abundance Capital (Greenville), OneBio Venture Studio, University of California, Los Angeles, Healthspan Capital, and University of Toronto have invested in Metanoia.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process